LGND analyst estimates
Ligand Pharmaceuticals (LGND) analyst ratings, the average price target and its range, and every firm's latest call.
LGND analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 29, 2026 | Stifel Nicolaus | Ligand Pharma (LGND) PT Raised to $350 at Stifel | $350.00 |
| Sep 25, 2026 | Barclays | Barclays Starts Ligand Pharma (LGND) at Overweight | $345.00 |
| Aug 14, 2026 | Leerink Partners | Ligand initiated with an Outperform at Leerink | $330.00 |
| Aug 6, 2026 | H.C. Wainwright | Ligand price target raised to $358 from $289 at H.C. Wainwright | $358.00 |
| Aug 3, 2026 | Oppenheimer | Ligand Pharma (LGND) PT Raised to $326 at Oppenheimer | $326.00 |
| Jul 20, 2026 | Craig-Hallum | Ligand price target raised to $345 from $330 at Craig-Hallum | $345.00 |
| Jul 15, 2026 | RBC Capital | Ligand price target raised to $340 from $262 at RBC Capital | $340.00 |
| Jul 8, 2026 | Stifel Nicolaus | Ligand price target raised to $332 from $255 at Stifel | $332.00 |
| Apr 30, 2026 | H.C. Wainwright | Ligand price target raised to $289 from $243 at H.C. Wainwright | $289.00 |
| Apr 28, 2026 | RBC Capital | Ligand price target raised to $252 from $235 at RBC Capital | $252.00 |
| Apr 27, 2026 | Stifel Nicolaus | Ligand price target raised to $255 from $230 at Stifel | $255.00 |
| Apr 14, 2026 | H.C. Wainwright | Ligand price target raised to $243 from $239 at H.C. Wainwright | $243.00 |
| Feb 24, 2026 | H.C. Wainwright | Ligand price target raised to $239 from $231 at H.C. Wainwright | $239.00 |
| Dec 10, 2025 | Oppenheimer | Oppenheimer Reiterates Outperform Rating on Ligand Pharma (LGND) | $275.00 |
| Dec 10, 2025 | Stifel Nicolaus | Ligand price target raised to $230 from $220 at Stifel | $230.00 |
- 9 firms rate LGND: 9 buy, 0 hold, 0 sell.
- The average price target is $342.00 from 7 analysts, from $326.00 to $358.00.
Updated 2026-11-02 23:11 UTC